
How do vaccines work? Medical experts explain.
How do vaccines work? Medical experts explain.
Show Caption
Hide Caption
Robert F. Kennedy Jr. posts endorsement of measles MMR vaccine on X
Health and Human Services secretary, and vaccine skeptic, Robert F. Kennedy Jr. supports measles vaccine after visiting West Texas.
Medical experts repeatedly reiterate how vital vaccinations are to global health. As of last spring, the World Health Organization (WHO) estimated that worldwide immunization efforts have saved at least 154 million people's lives over the past 50 years.
But despite vaccines having a "long history of successfully protecting people and communities against infectious diseases," per the Centers for Disease Control and Prevention (CDC), some hesitancy – and sometimes outright opposition – around them remains.
"Since the outbreak of the COVID-19 pandemic, we have seen a shift in the perception of vaccines. Misinformation about health, and especially about vaccines, is prevalent," says Dr. Jennifer Brull, president of the American Academy of Family Physicians (AAFP).
Being vaccinated for a certain illness also decreases a person's chance of contracting that illness. And if they do get it anyway, the CDC says they're "less likely to die or become seriously ill than someone whose immune system is unprepared to fight an infection."
A 2023 survey of local U.S. health departments, conducted by the National Association of County and City Health Officials (NACCHO), found that more than 80% of local departments reported experiencing challenges with patients and/or parents being hesitant toward vaccinations. That's nearly a 40% increase from their 2017 survey results.
"Vaccines are safe, effective and save lives," Brull adds. "They are one of our best tools to prevent severe illness, hospitalizations and death in our communities. ... Being vaccinated against diseases helps build a community of immunity and protects those more vulnerable to disease who may not be able to get vaccinated."
Here's everything medical experts want you to know about how vaccines work.
In case you missed: RFK Jr. claims 'leaky' measles vaccine wanes over time. Scientists say he's wrong.
What is a vaccine? How do vaccines work?
Vaccines work by imitating an infection to teach the body how to recognize and defend itself from disease without experiencing the dangers of an actual infection, according to the CDC.
"They do so by exposing the body to an active ingredient called an antigen which triggers an immune response," Brull says. Depending on the vaccine, "this immune response can protect you for many years or your entire life."
They exist for all kinds of diseases, including measles and whooping cough, among many others, and have different formulations.
What is Tdap? Here's what you need to know to stay protected against whooping cough
Are vaccines safe?
Side effects may cause tiredness, fever or a sore arm at the injection site for a day or two, but medical experts want to assure you that it just means the vaccine is working. If you have a more serious reaction, you should call your doctor. But most of the time, reactions are nothing to worry about.
"Instead of a mild reaction deterring you from getting future vaccines, it should encourage you," Brull says. "That's the vaccine working and jumpstarting your body's immune system."
Brull encourages those who have questions or concerns about vaccines to speak with a properly qualified and certified medical expert. They're prepared to have an "honest conversation" and listen to your concerns while providing accurate information and can debunk unfounded claims.
"As trusted messengers in our communities, we can help dispel myths and misconceptions about vaccines," she says. "Your family physician can help answer questions you may have about information you see online or hear from friends and family."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
US FDA approves Merck's RSV antibody for infants
(Reuters) -The U.S. Food and Drug Administration on Monday approved Merck's preventive antibody shot to protect infants up to one year of age from respiratory syncytial virus during their first RSV season, the company said. The United States has seen limited supply of Sanofi and AstraZeneca's antibody Beyfortus, the only preventive shot for RSV available in the country for infants and toddlers so far. Merck's therapy, called clesrovimab and branded as Enflonsia, is a monoclonal antibody that can be administered as a single dose regardless of birth weight in healthy pre-term, full-term and at-risk infants to protect them against mild, moderate and severe RSV. RSV is a common respiratory virus that causes seasonal infections such as the flu, but is a leading cause of pneumonia and death in infants and older adults. The approval was based on results from a late-stage trial in which Enflonsia had a comparable safety profile to Swedish Orphan Biovitrum's Synagis, a monthly injection. Merck said that Enflonsia is the first and only RSV preventive option administered to infants using the same dose regardless of weight, and it told Reuters the drug will be priced at $556 per dose. Jefferies analyst Akash Tewari said last year that this is beneficial since physicians have to forecast an infant's potential weight during RSV season with Beyfortus, which makes dose ordering and inventory more complex. In the U.S., an estimated 58,000–80,000 children younger than five years are hospitalized due to RSV each year, according to the U.S. Centers for Disease Control and Prevention. The CDC currently recommends two immunization options for babies to be protected from severe RSV — an RSV vaccine given to the mother during pregnancy or an RSV antibody given to the baby. Merck expects the drug's shipments to arrive in time for the 2025-2026 RSV season. The CDC's Advisory Committee on Immunization Practices is expected to meet later this month to discuss and make recommendations for the use of Enflonsia in infants.
Yahoo
an hour ago
- Yahoo
3 Healthcare Stocks Skating on Thin Ice
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, and over the past six months, the industry has pulled back by 12.3%. This performance was noticeably worse than the S&P 500's 1.9% fall. Investors should tread carefully as the influx of venture capital has also ushered in a new wave of competition. Taking that into account, here are three healthcare stocks we're swiping left on. Market Cap: $48.91 billion With a history dating back to 1897 and a presence in virtually every hospital around the globe, Becton Dickinson (NYSE:BDX) develops and manufactures medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions and professionals worldwide. Why Do We Think Twice About BDX? Annual sales growth of 4.1% over the last five years lagged behind its healthcare peers as its large revenue base made it difficult to generate incremental demand 10.5 percentage point decline in its free cash flow margin over the last five years reflects the company's increased investments to defend its market position Below-average returns on capital indicate management struggled to find compelling investment opportunities BD is trading at $170.95 per share, or 11.4x forward P/E. If you're considering BDX for your portfolio, see our FREE research report to learn more. Market Cap: $8.28 billion With a unique business model combining end-of-life care and household services, Chemed (NYSE:CHE) operates two distinct businesses: VITAS, which provides hospice care for terminally ill patients, and Roto-Rooter, which offers plumbing and water restoration services. Why Does CHE Fall Short? 4.6% annual revenue growth over the last five years was slower than its healthcare peers Capital intensity has ramped up over the last five years as its free cash flow margin decreased by 8.9 percentage points Waning returns on capital imply its previous profit engines are losing steam At $568.39 per share, Chemed trades at 22x forward P/E. Read our free research report to see why you should think twice about including CHE in your portfolio, it's free. Market Cap: $10.73 billion Formerly known as PerkinElmer until its rebranding in 2023, Revvity (NYSE:RVTY) provides health science technologies and services that support the complete workflow from discovery to development and diagnosis to cure. Why Is RVTY Risky? Organic sales performance over the past two years indicates the company may need to make strategic adjustments or rely on M&A to catalyze faster growth Day-to-day expenses have swelled relative to revenue over the last five years as its adjusted operating margin fell by 8.8 percentage points Eroding returns on capital suggest its historical profit centers are aging Revvity's stock price of $91.03 implies a valuation ratio of 17.6x forward P/E. Check out our free in-depth research report to learn more about why RVTY doesn't pass our bar. Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today for free. Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
US FDA approves Merck's RSV antibody for infants
(Reuters) -The U.S. Food and Drug Administration on Monday approved Merck's preventive antibody shot to protect infants up to one year of age from respiratory syncytial virus during their first RSV season, the company said. The United States has seen limited supply of Sanofi and AstraZeneca's antibody Beyfortus, the only preventive shot for RSV available for infants and toddlers so far. Merck's therapy, called clesrovimab and branded as Enflonsia, is a monoclonal antibody that can be administered as a single dose regardless of birth weight in healthy pre-term, full-term and at-risk infants to protect them against mild, moderate and severe RSV. RSV is a common respiratory virus that causes seasonal infections such as the flu, but is a leading cause of pneumonia and death in infants and older adults. Each year in the United States, an estimated 58,000–80,000 children younger than five years are hospitalized due to RSV, according to the U.S. Centers for Disease Control and Prevention. The CDC currently recommends two immunization options for babies to be protected from severe RSV — an RSV vaccine given to the mother during pregnancy or an RSV antibody given to the baby. Merck expects the drug's shipments to arrive in time for the 2025-2026 RSV season. The CDC's Advisory Committee on Immunization Practices is expected to meet later this month to discuss and make recommendations for the use of Enflonsia in infants.